Distinguished in Myeloproliferative Neoplasms (MPN)

Anna L. Godfrey

Cambridge, ENG, GB 
Distinguished in Myeloproliferative Neoplasms (MPN)
Cambridge, ENG, GB 
OverviewLocationsClinical Research

Overview

Anna Godfrey practices in Cambridge, United Kingdom. Ms. Godfrey is rated as a Distinguished expert by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). Her top areas of expertise are Myeloproliferative Neoplasms (MPN), Essential Thrombocythemia, Polycythemia Vera, and Myelofibrosis.

Her clinical research consists of co-authoring 58 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 17 articles and participated in 1 clinical trial in the study of Myeloproliferative Neoplasms (MPN).

Gender
Female

Locations

Cambridge, ENG, United Kingdom
Other Locations
London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drugs: CPI-0610, Rituximab
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2024
Intervention Type: Drug
Study Drugs: CPI-0610 BET Small Molecule Inhibitor, Ruxolitinib
Study Phase: Phase 3
View 1 Less Clinical Trial

58 Total Publications

Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesis.
Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesis.
Journal: Nature genetics
Published: June 09, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Godfrey's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile